Dr. Brownstein, an esteemed epidemiologist, researcher at Boston Children's Hospital and professor at Harvard Medical School, will assist on MINDCURE's digital technology, data optimization and patient data security within iSTRYM, its psychedelic digital therapeutics platform

Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company") a leader in advanced proprietary technology for psychedelic therapy, is pleased to announce the addition of Dr. John Brownstein as Advisor to the Company. Dr. Brownstein, the Chief Innovation Officer at Boston Children's Hospital and a Professor of Medicine at the Harvard Medical School, is world-renowned for his pioneering approach to data management and technology within health care. The HealthMap system he founded was the first electronic disease surveillance program to issue an alert for COVID-19 in late December of 2019. Dr. Brownstein and his team also run Vaccine Finder, a platform to help people more easily find clinics and pharmacies that offer COVID-19 vaccinations.

In his role as Advisor, Dr. Brownstein will help to inform the development and deployment of iSTRYM, MINDCURE's psychedelics digital therapeutics platform, and related technologies. Dr. Brownstein is also published extensively on issues of patient privacy, and his expertise will enable MINDCURE to best optimize the translation and utilization of patient data collected through iSTRYM, with the intended goal to uncover optimal protocols and treatment methods.

"I am thrilled to be joining the MINDCURE team today as an Advisor. With iSTRYM, MINDCURE is creating a platform to improve mental health treatments across the globe through better understanding patient and research data within psychedelics, with the hope of unlocking tremendous value for researchers, therapists, and ultimately patients in need," said Dr. John Brownstein. "I believe that my experience of building technology to better collect, understand, and unlock insights from large patient data sets across the globe will enable MINDCURE to build iSTRYM into a valuable resource for the entire psychedelics industry."

"Dr. Brownstein understands the opportunity we have to improve efficacy in the medical field by putting real-world data to use," said Kelsey Ramsden, President & CEO, MINDCURE. "It is early days for this in the psychedelics industry, but we see an amazing opportunity for iSTRYM to become the go-to platform of choice for researchers, therapists and patients around the world. We are honoured that Dr. Brownstein will be joining us as an Advisor. His credentials, experience, and track record speak for themselves and his contributions to the global medical community are unrivaled."

About Dr. John Brownstein

Dr. Brownstein is the Chief Innovation Officer of Boston Children's Hospital and Professor of Biomedical Informatics at Harvard Medical School. He also directs the Computational Epidemiology Lab and the Innovation and Digital Health Accelerator both at Boston Children's. He was trained as an epidemiologist at Yale University. Overall, his work aims to have translation impact on the surveillance, control and prevention of disease. He has been at the forefront of the development and application of data mining and citizen science to public health. His efforts are in use by millions each year including the CDC, WHO, DHS, DOD, HHS, and EU, and has been recognized by the National Library of Congress and the Smithsonian. In addition to research achievements, this translational impact comes from playing an advisory role to numerous agencies on real-time public health surveillance including HHS, DHS, CDC, IOM, WHO and the White House.

He was awarded the Presidential Early Career Award for Scientists and Engineers, the highest honor bestowed by the United States government to outstanding scientists and the Lagrange Prize for international achievements in complexity sciences. Dr. Brownstein is co-founder of digital health companies Epidemico and Circulation. He has authored over 250 peer-reviewed articles on epidemiology and public health. This work has been reported on widely including pieces in the New England Journal of Medicine, Science, Nature, New York Times, The Wall Street Journal, CNN, National Public Radio and the BBC.

The Company also announces it has granted a total of 360,000 stock options to certain employees or consultants pursuant to the terms the Company's incentive stock option plan ("Plan"). The stock options are exercisable: 10,000 at a price of $0.60 per share, 250,000 at a price of $0.38 per share and 100,000 at a price of $0.32 per share and are subject to the terms of the Plan.

About Mind Cure Health (MINDCURE) Inc.

MINDCURE exists as a response to the current mental health crisis and urgent calls for effective treatments. MINDCURE believes in the need to reinvent the mental health care model for patients and practitioners to allow psychedelics to advance into common and accepted care.

MINDCURE is focused on identifying and developing pathways and products that ease suffering, increase productivity, and enhance mental health. MINDCURE is interested in exploring diverse therapeutic areas beyond psychiatry, including digital therapeutics, neuro-supports, and psychedelics, all to improve mental health.

On Behalf of the Board of Directors
Kelsey Ramsden, President & CEO
Phone: 1-888-593-8995

Forward-Looking Information

Certain statements in this news release may constitute "forward-looking information" within the meaning of applicable securities laws (also known as forward-looking statements). Forward-looking information involves known and unknown risks, uncertainties and other factors, and may cause actual results, performance or achievements or industry results, to be materially different from any future results, performance or achievements or industry results expressed or implied by such forward-looking information. Forward-looking information generally can be identified by the use of terms and phrases such as "anticipate", "believe", "could", "estimate", "expect", "feel", "intend", "may", "plan", "predict", "project", "subject to", "will", "would", and similar terms and phrases, including references to assumptions. Some of the specific forward-looking information in this news release includes, but is not limited to, statements with respect to: Dr. Brownstein assisting MINDCURE on its digital technology, data optimization and patient security within iSTRYM; MINDCURE optimizing the translation and utilization of patient data collected through iSTRYM; and MINDCURE building iSTRYM into a valuable resource for the entire psychedelics industry.

Forward-looking information is based on a number of key expectations and assumptions made by MINDCURE, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and MINDCURE's business, and the extent and duration of such impact; no change to laws or regulations that negatively affect MINDCURE's business; there will be a demand for MINDCURE's products in the future; no unanticipated expenses or costs arise; MINDCURE will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; that the functional mushroom industry will continue to grow; Dr. Brownstein assisting MINDCURE on its digital technology, data optimization and patient security within iSTRYM; MINDCURE optimizing the translation and utilization of patient data collected through iSTRYM; and MINDCURE will be able to operate its business as planned. Although the forward-looking information contained in this news release is based upon what MINDCURE believes to be reasonable assumptions, it cannot assure investors that actual results will be consistent with such information.

Forward-looking information is provided for the purpose of presenting information about management's current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward-looking information involves significant risks and uncertainties and should not be read as a guarantee of future performance or results as actual results may differ materially from those expressed or implied in such forward-looking information. Those risks and uncertainties include, among other things, risks related to: the impacts of the COVID-19 pandemic on the Canadian economy, MINDCURE's industry and MINDCURE's business, which may negatively impact, and may continue to negatively impact, MINDCURE and may materially adversely affect MINDCURE's investments, results of operations, financial condition, and MINDCURE's ability to obtain additional equity or debt financing, and satisfy its financial obligations; general economic conditions; future growth potential; competition for mental health and wellness investments; Dr. Brownstein may not assist MINDCURE on its digital technology, data optimization and patient security within iSTRYM; MINDCURE may not optimize the translation and utilization of patient data collected through iSTRYM; and MINDCURE building iSTRYM into a valuable resource for the entire psychedelics industry.; and changes in legislation or regulations. Management believes that the expectations reflected in the forward-looking information contained herein are based upon reasonable assumptions and information currently available; however, management can give no assurance that actual results will be consistent with such forward-looking information. Additional information on the risk factors that could affect MINDCURE can be found under "Risk Factors" in MINDCURE's final prospectus which is available on SEDAR at www.sedar.com.

The forward-looking information contained herein is expressly qualified in its entirety by this cautionary statement. Forward-looking information reflects management's current beliefs and is based on information currently available to MINDCURE. The forward-looking information is stated as of the date of this news release and MINDCURE assumes no obligation to update or revise such information to reflect new events or circumstances, except as may be required by applicable law.

United States Advisory

The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), may be offered and sold outside the United States to eligible investors pursuant to Regulation S promulgated under the U.S. Securities Act, and may not be offered, sold, or resold in the United States or to, or for the account of or benefit of, a U.S. Person (as such term is defined in Regulation S under the United States Securities Act) unless the securities are registered under the U.S. Securities Act, or an exemption from the registration requirements of the U.S. Securities Act is available. Hedging transactions involving the securities must not be conducted unless in accordance with the U.S. Securities Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in the state in the United States in which such offer, solicitation or sale would be unlawful.

The CSE has neither approved nor disapproved the contents of this press release and the CSE does not accept responsibility for the adequacy or accuracy of this release.